ISCP 2018, Kyoto – Full Program

Videos of many of the speakers and sessions is available below. Please click on the links highlighted in red below, where available, to view footage of the meeting.

Opening Remarks

Koji Hasegawa, Chair of 23rd ISCP Kyoto 2018, President of ISCP

Future Pharmacotherapy for Atherosclerosis: Basic Science for the Clinician


Kensuke Noma, Hiroshima, Japan
Morihiro Matsuda, Kure, Japan


Tatsuya Sawamura, Nagano, Japan: Modified Lipoproteins and LOX-1 in Cardiovascular Disease
Noboru Ashida, Kyoto, Japan: Role of inflammatory signaling in vascular calcification
Tetsuya Matoba, Fukuoka, Japan: Ezetimibe ameliorates coronary endothelial dysfunction through decreases in oxysterols
Koh Ono, Kyoto, Japan: SREBF1/MicroRNA-33b axis exhibits potent effect on unstable atherosclerotic plaque formation in vivo

Joint Panel Discussion
ESC Working Group on Cardiovascular Pharmacotherapy:
Cardiac and Systemic Linkage for the Control of Hypertension


Heinz Drexel, Austria
Koji Hasegawa, Kyoto, Japan


Thomas Kahan, Sweden: Hypertensive heart disease
Stefan Agewall, Norway: Effective at last – The new glucose-lowering drugs that reduce CV events
Celso Amodeo, Brazil: Resistant hypertension
Junichi Oyama, Saga, Japan: Sleep apnea syndrome

Seminar supported by GSK: Pulmonary Hypertension


Atsushi Nakano, Japan


Carlos Jardim, Brazil
Hiromi Matsubara, Okayama, Japan

Panel Discussion:
Prevention of Atherosclerotic Events by Targeting Lipid Metabolism and Inflammation


Juan Carlos Kaski, UK
Celso Amodeo, Brazil


Watch video >
Heinz Drexel, Austria: PCSK9-inhibitors for which patient?

Watch video >
Masaaki Kawashiri, Kanazawa, Japan: Familiar Hypercholesterolemia

Watch video >
Alberto Lorenzatti, Argentina: Anti-inflammatory drugs: niche treatment or broad application?

Meet the Experts – pharmacotherapy challenges


Koji Hasegawa and Juan Carlos Kaski


George Dan, Thomas Kahan, Antoni Martinez Rubio, Felipe Martìnez.


What is the best strategy for the management of HFpEF?
Should we use a same type of anticoagulant for all patients with AF?
PCSK9 Inhibitors: Indications and timing
Are β-blockers useful for the management of systemic hypertension?

Joint WHF/ISCP Plenary Session:
Global Cardiovascular Risk Management to Achieve ‘25 by 25’

Chairs and Modulators:

Jean-Luc Eiselé, CEO, World Heart Federation
Koji Hasegawa, President, ISCP

Opening Remarks:

Watch video >
Chuichi Kawai, Past President of World Heart Federation

Speakers and Discussants:

Watch video >
Katsuyuki Miura, Shiga, Japan:Global Epidemiology in Cardiovascular Risk Factors

Watch video >
Alvaro S. Liprandi, Argentina: Roadmaps to Achieve ‘25 by 25’ ─ Global and Regional Coalitions

Watch video >
Shinji Koba, Tokyo, Japan: The Role of Exercise for Cardiovascular Prevention

Watch video >
Maki Komiyama, Kyoto, Japan: Smoking and depression in Cardiovascular Disease

Watch video >
Edgardo Escobar, Chile: Telemedicine to Reduce Mortality in Heart Attacks

Watch video >
Plenary session Discussions

Henry N. Neufeld Memorial Award Lecture:

Watch video >
Lina Badimon, Catalan Institute of Cardiovascular Sciences (ICCC), Spanish National Research Council (CSIC)
Precision Medicine: Molecular Phenotyping in Cardiovascular Pharmacotherapy

Reprograming and Regeneration of the Heart: Basic Science for the Clinician


Tatsuya Morimoto, Shizuoka Japan
Shuhei Tomita, Osaka, Japan


Teruhisa Kawamura, Kyoto, Japan: Dissecting the Process of Metabolic Shift during iPS Cell Reprogramming
Junko Kurokawa, Shizuoka, Japan: Electrophysiological maturation of human iPS-derived cardiomyocytes
Masaki Ieda, Ibaraki, Japan: Direct Cardiac Reprogramming and Heart Regeneration
Takeru Makiyama, Kyoto, Japan: Modelling long-QT syndrome with human iPS cells and development of new pharmacotherapies

Joint session of ISCP and ISCMF
Recent Advances in Cardiomyopathies, Myocarditis and Heart Failure


Mario Maranhao, Brazil
Peter Schultheiss, Germany


Akira Matsumori, Kyoto, Japan: New biomarkers of inflammation and cardiovascular risk
Peter Liu, Ottawa, Canada: Genetic and Protein Biomarkers in the Diagnosis and Management of Cardiomyopathies and Heart Failure
Andre Keren, Israel: Clinical implications of the new European definition of dilated cardiomyopathy
Leslie Cooper, USA: The Evolving Role for Nuclear Imaging in Unexplained Cardiomyopathy
Peter Schultheiss, Germany: Modelling long-QT syndrome with human iPS cells and development of new pharmacotherapies

Up-to-date Topics of Atrial Fibrillation and Anti-coagulant Therapy


Felipe Martinez, Argentina


Masaharu Akao, Kyoto, Japan: Risk stratification of atrial fibrillation in Asia
Dalmo Moreira, Brazil: Is there a role for the nonvit K antagonist in the prevention of atrial fibrillation? 

Pharmacotherapy and Life-style Modification for Heart Failure: the Present and the Future


Shigetake Sasayama, Kyoto, Japan
Yasushi Fujio, Osaka, Japan


Sang Hong Baek, Korea: Myocardial fibrosis and new options for treatment
Felipe Martinez, Argentina: New drugs in heart failure: more of the same or the beginning of a new era?
Takuya Kishi, Fukuoka, Japan: Cardiac linkage with brain and autonomic nervous system

Cardiovascular Imaging Guiding Pharmacotherapy


Alberto Lorenzatti, Argentina
Masataka Sata, Tokushima, Japan


Augusto Gallino, Switzerland: Role of imaging in developing new drugs
Takashi Akasaka, Wakayama, Japan: Optical coherence tomography
Mitsuyasu Terashima, Aiti, Japan: Intravascular Ultrasound

Panel Discussion:
Controversies in Anti-coagulant Therapy in Atrial Fibrillation and Venous Thromboembolism


George A. Dan, Romania
Takanori Ikeda, Tokyo, Japan


Ali Oto, Turkey: Risk stratification of stroke in AF
Antoni Martinez-Rubio Barcelona, Spain: DOAC for AF
Shinji Hisatake, Tokyo, Japan: DOAC for VTE

Panel Discussion
Treatment of Atrial Fibrillation: the Place of Antiarrhythmic Drugs


Ali Oto, Turkey
Atsushi Sugiyama, Tokyo, Japan


George A. Dan, Romania: Antiarrhythmic drugs
Naohiko Takahashi, Oita, Japan: Inflammation in AF

Joint Workshop with Asian Pacific Society of Cardiology (APSC)
Prediction and Prevention of Sudden Cardiac Death and Syncope


Jiunn-Lee Lin, Taiwan (from APSC)
Nannette R. Rey, Philippine (from ISCP)


Watch video >
Anca Dan, Romania: Syncope: Diagnosis and risk stratification

Watch video >
Naohiko Takahashi, Oita, Japan: Sudden cardiac death in J-wave syndrome

Watch video >
Takanori Ikeda, Tokyo, Japan: Prediction of sudden cardiac death

Watch video >
Joint workshop: Discussion

Award Ceremony for Best Abstract Presentation

Cavin-2 Deficiency Attenuates Cardiac Fibrosis and Dysfunction in Pressure-overloaded Hearts
Yusuke Higuchi, Takehiro Ogata, Masahiro Nishi, Satoaki Matoba

Comparative Analysis of the Effects EPA and DHA on Cultured Cardiomyocyte
Ayumi Katayama, Masafumi Funamoto, Kana Shimizu1, Mai Gempei, Yoichi Sunagawa, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto

3D Ultrastructure of the “Arrhythmogenic” Purkinje Fibre-ventricular Junction in Rabbit Hearts
Shu Nakao, Il-Young Oh, Luke Stuart, Hiren Sitpura, Joseph Yanni, Sunil JSR Logantha, Xue Cai, Tobias Starborg, Halina Dobrzynski, Ashraf Kitmitto, Mark R Boyett

Closing Remarks

Augusto Gallino, Chair, 24th ISCP Switzerland 2019

Please visit the ISCP 2019 website for details of the 2019 meeting in Lugano

Drug Management of Coronary Vasospasm, Microvascular Angina and Takotsubo Cardiomyopathy


Masatoshi Fujita, Kyoto, Japan
Masataka Sata, Tokushima, Japan


Juan Carlos Kaski, UK: Microvascular angina
Sang Hong Baek, Korea: Coronary vasospasm
Yoshihiro Akashi, Kanagawa, Japan: Takotsubo cardiomyopathy

Joint Symposium with Asian Pacific Society of Cardiology (APSC)
Biomarkers to Predict Acute Coronary Syndrome, Atherosclerosis and Heart Failure


San-Jou Yeh, Taiwan (from APSC)
Jorge A. Sison, Philippine (from ISCP)


Bernard MY Cheung, Hong Kong: Biomarkers for acute coronary syndrome – are they good enough?
Augusto Gallino, Switzerland
Hiromichi Wada, Kyoto, Japan: Vascular endothelial growth factor-C and mortality in patients with suspected coronary artery disease

Anti-thrombotic Therapy during and after Coronary Intervention


Augusto Gallino, Switzerland
Doreen Tan, Singapore


Bernard MY Cheung, Hong Kong: Resolving the controversy on optimal duration of dual antiplatelet therapy after coronary intervention
Antoni Martinez-Rubio, Barcelona, Spain: DOAC in coronary artery disease
Isao Taguchi, Saitama, Japan: Optimal anti-thrombotic therapy after PCI

Governor’s Meeting

World Tobacco No Day Memorial Session:
Tobacco and heart disease


Keijiro Saku, Kyoto Japan
Tatsuya Morimoto, Shizuoka Japan

Speakers and Discussants:

Toyoaki Murohara, Aichi Japan: Tobacco and cardiovascular disease
Rei Goto, Tokyo Japan: Cost-benefit Effectiveness on Smoking Cessation
Lisa Demos, Australia: Pharmacotherapy and Australian initiatives for smoking cessation

Cardiac metabolism and mitochondria


Satoaki Matoba, Kyoto Japan
Hiroshi Kondo, Kyoto Japan


Osamu Yamaguchi, Ehime, Japan: Mitochondria degradation as a novel therapeutic target for heart failure
Masaya Tanno, Hokkaido, Japan: Regulation of mitochondrial GSK-3β activity by kinases, phosphatases and a deacetylase: a key determinant for mitochondrial permeability transition
Ippei Shimizu, Niigata Japan: The pathological role of brown adipose tissue dysfunction in cardio-metabolic disorders
Atsushi Hoshino, Kyoto Japan: Essential mitochondrial components to induce mitophagy